István Láng

18.8k citations

113 papers · 7.0k indexed · 5 hit papers · h-index 34

Impact in

Oncology top 0.2%
- Colorectal Cancer Treatments and Studies
- HER2/EGFR in Cancer Research
- Cancer Treatment and Pharmacology
Cancer Research top 0.5%
- Breast Cancer Treatment Studies

Papers in

Oncology 90
- Cancer Treatment and Pharmacology 43
- HER2/EGFR in Cancer Research 32
- Colorectal Cancer Treatments and Studies 24
Cancer Research 42
- Breast Cancer Treatment Studies 38

Co-authors: Richard D. Gelber David Cunningham Eric Van Cutsem Philippe Rougier Gunnar Folprecht Claus-Henning Köhne Fortunato Ciardiello Joan Maurel
Journals: Journal of Clinical Oncology (29 papers)Cancer Research (14 papers)Annals of Oncology (11 papers)The Lancet Oncology (6 papers)Pathology & Oncology Research (4 papers)
Partner nations: Hungary United States Switzerland

In The Last Decade

István Láng

110 papers receiving 6.8k citations

Hit Papers

5 papers align trajectories log scale

Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer 2017 · 918 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2017 New England Journal of Medicine
2013 The Lancet Oncology
2011 Journal of Clinical Oncology
2010 Journal of Clinical Oncology
2007 Journal of Clinical Oncology

Peers

Countries citing papers authored by István Láng

Since Specialization

Citations

This map shows the geographic impact of István Láng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by István Láng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites István Láng more than expected).

Fields of papers citing papers by István Láng

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by István Láng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by István Láng. The network helps show where István Láng may publish in the future.

Co-authorship network

The 25 scholars most cited alongside István Láng, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with István Láng Line = papers co-authored together István Láng links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Lapatinib with ECF/X in the first-line treatment of metastatic gastric cancer according to HER2neu and EGFR status: a randomized placebo-controlled phase II study (EORTC 40071) Cancer Chemotherapy and Pharmacology ·(unknown), Markus Moehler, Arno Schad, Annett Maderer, Ajlan Atasoy, Murielle Mauer, Carmela Caballero, Thomas Thomaidis, Jestinah Mahachie John, István Láng, Eric Van Cutsem, Le Yang, Manfred P. Lutz, Arnaud Roth	2018	13
2	Lapatinib-Related Rash and Breast Cancer Outcome in the ALTTO Phase III Randomized Trial JNCI Journal of the National Cancer Institute ·Amir Sonnenblick, Evandro de Azambuja, Dominique Agbor‐Tarh, Ian Bradbury, Christine Campbell, Yingjie Huang, Amylou C. Dueck, Kathleen I. Pritchard, Antonio C. Wolff, Christian Jackisch, István Láng, Michael Untch, Ian Smith, Frances Boyle, Binghe Xu, Henry Gómez, Edith A. Perez, Martine Piccart, Hatem A. Azim	2016	22
3	Predictive role of hand–foot syndrome in patients receiving first-line capecitabine plus bevacizumab for HER2-negative metastatic breast cancer British Journal of Cancer ·Christoph Zielinski, István Láng, S. Beslija, Zsuzsanna Kahán, Moshe Inbar, Salomon M. Stemmer, Keichi Kawano, Damir Vrbanec, Diethelm Messinger, Thomas Brodowicz	2015	21
4	Serum estrone concentration, estrone sulfate/estrone ratio and BMI are associated with human epidermal growth factor receptor 2 and progesterone receptor status in postmenopausal primary breast cancer patients suffering invasive ductal carcinoma SpringerPlus ·Cade A. Cantu, Isabel María de la Torre Gálvez, Nóra Udvarhelyi, Zsolt Horváth, Zoltán Mátrai, Ferenc Czeyda‐Pommersheim, Patcharon Tanawattanacharoen, Hye Sin An, Jan M. Metzler, István Láng, Miklós Kásler	2015	4
5	Selecting first-line bevacizumab-containing therapy for advanced breast cancer: TURANDOT risk factor analyses British Journal of Cancer ·Thomas Brodowicz, István Láng, Zsuzsanna Kahán, Richard Greil, S. Beslija, Salomon M. Stemmer, Bella Kaufman, Luboš Petruželka, Alexandru Eniu, Keichi Kawano, Krassimir Koynov, D. Vrbanec, Tadeusz Pieńkowski, Bohuslav Melichar, S. Špánik, Hubert Weibel, Diethelm Messinger, Moshe Inbar, Christoph Zielinski	2014	24
6	A phase two randomised trial of neratinib monotherapy versus lapatinib plus capecitabine combination therapy in patients with HER2+ advanced breast cancer European Journal of Cancer ·Miguel Martín, Jacques Bonneterre, Charles E. Geyer, Yoshinori Ito, Jungsil Ro, István Láng, Sung‐Bae Kim, Caroline Germa, Jennifer Vermette, Н.В. Мартинович, Kongming Wang, Ahmad Awada	2013	119
7	CNS relapses in patients with HER2-positive early breast cancer who have and have not received adjuvant trastuzumab: a retrospective substudy of the HERA trial (BIG 1-01) The Lancet Oncology ·Bernhard C. Pestalozzi, Eileen Holmes, Evandro de Azambuja, Otto Metzger, Andrés Alejandro Ocampo Arbeláez, Jie Zhu, István Láng, Andrew Wardley, Mikhail Lichinitser, 李心峰, Volkmar Müller, David Dodwell, Richard D. Gelber, Martine Piccart, David Cameron	2013	142
8	Symptoms of endocrine treatment and outcome in the BIG 1-98 study Breast Cancer Research and Treatment ·(unknown), Jens Huober, Bernard F. Cole, Manuela Rabaglio, Anita Giobbie‐Hurder, ХАСБУЛАТОВ Ш.А., Bent Ejlertsen, Hervé Bonnefoi, JF Forbes, Patrick Neven, István Láng, Ian Smith, Andrew Wardley, Karen N. Price, Aron Goldhirsch, Alan S. Coates, Marco Colleoni, Richard D. Gelber, Beat Thürlimann	2013	33
9	Obesity and Risk of Recurrence or Death After Adjuvant Endocrine Therapy With Letrozole or Tamoxifen in the Breast International Group 1-98 Trial Journal of Clinical Oncology ·Marianne Ewertz, Kathryn P. Gray, Meredith M. Regan, Bent Ejlertsen, Karen N. Price, Beat Thürlimann, Hervé Bonnefoi, John Forbes, Robert Paridaens, Manuela Rabaglio, Richard D. Gelber, Marco Colleoni, István Láng, Ian E. Smith, Alan S. Coates, Aron Goldhirsch, Henning T. Mouridsen	2012	102
10	Abstract S3-2: Chemotherapy prolongs survival for isolated local or regional recurrence of breast cancer: The CALOR trial (Chemotherapy as Adjuvant for Locally Recurrent breast cancer; IBCSG 27-02, NSABP B-37, BIG 1-02) Cancer Research ·Stefan Aebi, Shari Gelber, István Láng, María Eugenia Villarreal, A. Robidoux, Marina Gracinda Modesto, 玉军张, EP Mamounas, CE Geyer, Rudolf Maibach, RD Gelber, Norman Wolmark, Irene Wapnir	2012	10
11	Significance of Histomorphology of Early Triple-Negative Breast Cancer Pathology & Oncology Research ·Gábor Rubovszky, Zsolt Horváth, Hyun Ki Hong, István Láng, Miklós Kásler	2012	3
12	Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status Journal of Clinical Oncology ·Eric Van Cutsem, Claus-Henning Köhne, István Láng, Gunnar Folprecht, Marek P. Nowacki, Stefano Cascinu, I. Shchepotin, Joan Maurel, David Cunningham, Sabine Tejpar, Michael Schlichting, Angela Zubel, Ilhan Celik, Philippe Rougier, Fortunato Ciardiello Hit paper breakdown →	2011	1441
13	Multicenter Phase III Comparison of Cisplatin/S-1 With Cisplatin/Infusional Fluorouracil in Advanced Gastric or Gastroesophageal Adenocarcinoma Study: The FLAGS Trial Journal of Clinical Oncology ·Jaffer A. Ajani, W. Rodriguez, G. Bodoky, Vladimir Moiseyenko, Mikhail Lichinitser, В. А. Горбунова, Ihor Vynnychenko, August Garin, István Láng, S. Falcon Hit paper breakdown →	2010	425
14	A tripla-negatív emlőkarcinóma – irodalmi áttekintés PubMed ·Gábor Rubovszky, Nóra Udvarhelyi, Zsolt Horváth, István Láng, Miklós Kásler	2010	2
15	Inflammatory Breast Cancer—Comparing the Effectivity of Preoperative Docetaxel-Epirubicine Protocol to Conventional Antracycline-Containing Chemotherapy to Achieve Clinical Benefit and Complete Pathological Response Pathology & Oncology Research ·Zsolt Horváth, László Torday, Erika Hitre, Feng Fua, É Juhos, Arshad Badfar, László Urbán, Csaba Polgár, István Láng, R. Gnanasekaran, Miklós Kásler	2010	4
16	A case-control study of gallbladder cancer in hungary. PubMed ·Hiroto Nakadaira, István Láng, Zoltán Szentirmay, Erika Hitre, Chee Chiang Ng, Masaharu Yamamoto	2009	14
17	Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial Annals of Oncology ·Manuela Rabaglio, Zijie Sun, Karen N. Price, Monica Castiglione‐Gertsch, Hanne Hawle, Beat Thürlimann, Henning T. Mouridsen, Mario Campone, JF Forbes, Robert Paridaens, Marco Colleoni, Tadeusz Pieńkowski, Jean‐Marie Nogaret, István Láng, Ian Smith, Richard D. Gelber, Aron Goldhirsch, Alan S. Coates	2009	133
18	Genetic changes of p53, K-ras, and microsatellite instability in gallbladder carcinoma in high-incidence areas of Japan and Hungary World Journal of Gastroenterology ·Masayuki Nagahashi, Yoichi Ajioka, István Láng, Zoltán Szentirmay, Miklós Kásler, Hiroto Nakadaira, Naoyuki Yokoyama, Gen Watanabe, Ken Nishikura, Toshifumi Wakai, Yoshio Shirai, Katsuyoshi Hatakeyama, Masaharu Yamamoto	2008	49
19	Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial Annals of Oncology ·L. Mauriac, Aparna Keshaviah, Marc Debled, Henning T. Mouridsen, John Forbes, Beat Thürlimann, R. Paridaens, Alain Monnier, István Láng, Andrew Wardley, Jean‐Marie Nogaret, RD Gelber, Monica Castiglione‐Gertsch, K.N. Price, Alan S. Coates, Ian Smith, Giuseppe Viale, Manuela Rabaglio, M. Wolf, Aron Goldhirsch	2007	106
20	[Clinical significance of bone marrow micrometastases of breast tumors]. PubMed ·Lifeng Lin, 下野裕之, Myong Hwa Kim, M.G. Maurizii, Gábor Péley, Eun Ja Chung, Zoltán Sulyok, István Láng, Hinzpeter En	2003	1

About István Láng

István Láng is a scholar working on Oncology, Cancer Research, Pulmonary and Respiratory Medicine, Genetics and Hepatology, having authored 113 papers that have together received 7.0k indexed citations. Recurring topics across this work include Cancer Treatment and Pharmacology (43 papers), Breast Cancer Treatment Studies (38 papers), HER2/EGFR in Cancer Research (32 papers), Advanced Breast Cancer Therapies (29 papers), Colorectal Cancer Treatments and Studies (24 papers), Estrogen and related hormone effects (14 papers), Lung Cancer Treatments and Mutations (7 papers) and Gastric Cancer Management and Outcomes (6 papers). The work is most often cited by research in Oncology (5.2k citations), Cancer Research (2.0k citations), Hepatology (605 citations), Pulmonary and Respiratory Medicine (2.3k citations) and Pathology and Forensic Medicine (999 citations). István Láng has collaborated with scholars based in Hungary, United States and Switzerland. Frequent co-authors include Richard D. Gelber, David Cunningham, Eric Van Cutsem, Philippe Rougier, Gunnar Folprecht, Claus-Henning Köhne, Fortunato Ciardiello, Joan Maurel, Ilhan Celik and Michael Schlichting. Their work appears in journals such as Journal of Clinical Oncology, Cancer Research, Annals of Oncology, The Lancet Oncology and Pathology & Oncology Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact